Response to Immune Checkpoint Inhibition in a Meningioma with DNA Mismatch Repair Deficiency

Overview

Journal Neurooncol Adv

Publisher Oxford University Press

Date 2024 Jul 3

PMID 38957162

Authors

Minh P Nguyen

Damian Almiron Bonnin

Kanish Mirchia

William C Chen

Ezequiel Goldschmidt

Steve E Braunstein

Arie Perry

David R Raleigh

Nancy Ann Oberheim Bush

Affiliations

Soon will be listed here.

Citing Articles

A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor.

Limon D, Amiel A, Haim S, Gordon N, Tschernichovsky R, Stemmer S Neurooncol Adv. 2024; 6(1):vdae154.

PMID: 39429970 PMC: 11487343. DOI: 10.1093/noajnl/vdae154.

References

Bi W, Nayak L, Meredith D, Driver J, Du Z, Hoffman S . Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2021; 24(1):101-113. PMC: 8730772. DOI: 10.1093/neuonc/noab118. View

Ostrom Q, Price M, Neff C, Cioffi G, Waite K, Kruchko C . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2023; 25(12 Suppl 2):iv1-iv99. PMC: 10550277. DOI: 10.1093/neuonc/noad149. View

Brastianos P, Galanis E, Butowski N, Chan J, Dunn I, Goldbrunner R . Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 2019; 21(Suppl 1):i18-i31. PMC: 6347080. DOI: 10.1093/neuonc/noy136. View

Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H . Genomic landscape of meningiomas. Brain Pathol. 2009; 20(4):751-62. PMC: 3167483. DOI: 10.1111/j.1750-3639.2009.00356.x. View

Ma X, Riaz N, Samstein R, Lee M, Makarov V, Valero C . Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nat Genet. 2022; 54(7):996-1012. PMC: 10181095. DOI: 10.1038/s41588-022-01108-w. View

Brastianos P, Horowitz P, Santagata S, Jones R, McKenna A, Getz G . Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013; 45(3):285-9. PMC: 3739288. DOI: 10.1038/ng.2526. View

Alexandrov L, Kim J, Haradhvala N, Huang M, Ng A, Wu Y . The repertoire of mutational signatures in human cancer. Nature. 2020; 578(7793):94-101. PMC: 7054213. DOI: 10.1038/s41586-020-1943-3. View

Chen W, Lucas C, Magill S, Rogers C, Raleigh D . Radiotherapy and radiosurgery for meningiomas. Neurooncol Adv. 2023; 5(Suppl 1):i67-i83. PMC: 10498143. DOI: 10.1093/noajnl/vdac088. View

Dunn I, Du Z, Touat M, Sisti M, Wen P, Umeton R . Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis Oncol. 2019; 2018. PMC: 6383717. DOI: 10.1200/PO.18.00190. View

10.

Brastianos P, Kim A, Giobbie-Hurder A, Quant Lee E, Wang N, Eichler A . Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022; 13(1):1325. PMC: 8921328. DOI: 10.1038/s41467-022-29052-7. View

11.

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

12.

Campbell B, Light N, Fabrizio D, Zatzman M, Fuligni F, De Borja R . Comprehensive Analysis of Hypermutation in Human Cancer. Cell. 2017; 171(5):1042-1056.e10. PMC: 5849393. DOI: 10.1016/j.cell.2017.09.048. View

13.

Clark V, Harmanci A, Bai H, Youngblood M, Lee T, Baranoski J . Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet. 2016; 48(10):1253-9. PMC: 5114141. DOI: 10.1038/ng.3651. View

14.

Germano G, Lamba S, Rospo G, Barault L, Magri A, Maione F . Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 2017; 552(7683):116-120. DOI: 10.1038/nature24673. View

15.

Robert C . A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020; 11(1):3801. PMC: 7393098. DOI: 10.1038/s41467-020-17670-y. View